Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 68Ga-FAPI-46 (Primary)
  • Indications Adenocarcinoma; Ductal carcinoma; Pancreatic cancer
  • Focus Diagnostic use
  • Acronyms FAPI-46 PDAC
  • Sponsors SOFIE

    • Most Recent Events

    • 15 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
    • 15 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 06 Jun 2023 According to a SOFIE media release, the company has added BAMF Health, a novel cancer treatment center in Grand Rapids, Michigan as latest site.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top